Research Journal of Medical Sciences 8 (1): 13-19, 2014

ISSN: 1815-9346

© Medwell Journals, 2014

Preventing Ventilator Associated Pneumonia (VAP) in a Pediatric Intensive Care Unit Using a Modified Ventilator Associated Pneumonia Bundle: Pre-Interventional and Post-Interventional Trial

Alaa Obeid, Amal Naous, Zeina Naja, Ahmad Salaheddine Naja, Bassem Abou Merhi and Mariam Rajab Department of Pediatrics, Makassed General Hospital, Beirut, Lebanon

Abstract: Ventilator associated pneumonia increases in hospital stay, morbidity and mortality of ventilated pediatric patients. It prolongs time spent on the ventilator and length of Pediatric Intensive Care Unit (PICV) stay. This is a pre-interventional and post-interventional trial of 57 and 50 pediatric patients, respectively which started in March 2011 to decrease the rate of ventilator associated pneumonia in Pediatric Intensive Care Unit after initiation of a modified pediatric VAP bundle compared with the ventilator associated pneumonia rate for the preceding 12 months. The study was conducted at Makassed General Hospital in Beirut, Lebanon. It included pediatric patients that were on mechanical ventilation from March 2010 to 2012. An interdisciplinary performance improvement team was formed who implemented a modified pediatric VAP bundle. The implementation of the pediatric VAP bundle resulted in the reduction of ventilator associated pneumonia rates from 52% (March 2010 to 2011) to 6% (March 2011 to 2012) (p<0.001). Patients who had VAP had longer stay on mechanical ventilation with a mean of 11.42 ventilator days than those who didn't develop ventilator associated pneumonia with a mean of 5.18 ventilator days (p<0.0001). Implementing the modified pediatric VAP bundle significantly reduced the ventilator associated pneumonia rate, time on mechanical ventilationand hospital length stay with potential decrease in cost.

Key words: Ventilator Associated Pneumonia (VAP), VAP prevention bundle, modified pediatric VAP bundle, pediatric intensive care unit, PICU

INTRODUCTION

Ventilator Associated Pneumonia (VAP) is defined by the Centers for Disease Controland Prevention (CDC) as an episode of pneumonia in a patient who requires a device to assist or control respiration through a tracheostomy or endotracheal tube within 48 h before the onset of the infection (CDC, 2005). Health care-associated infections have a large impact on pediatric morbidity, survival, hospital costs and length of stay (Payne *et al.*, 2004; Stoll *et al.*, 2004). VAP is a common cause and accounts for 6.8-50% of health care-acquired infections among pediatric patients (Van der Zwet *et al.*, 2005; Gaynes *et al.*, 1996; Drews *et al.*, 1995; Petdachai, 2004).

Ventilator Associated Pneumonia (VAP) is apotentially lethal and common problem among mechanically-ventilated patients in intensive care units. In addition to its high mortality rate compared to other nosocomial infections, VAP is associated with prolonged hospitalization and considerable medical costs (Vincent et al., 1995). Many factors predispose to acquiring VAP; infants mechanicallyventilated in the Pediatric Intensive Care Unit (PICU) are at a particularly

high risk of developing VAP because of poor host factors, severe underlying diseases, prolonged use of mechanical ventilation, inadequate pulmonary toilet and extensive use of invasive devices and procedures; gram-negative and gram-positive bacteria are themost common causative organisms (Grohskopf *et al.*, 2002).

Few data exist regarding the strategies that hospitals use to prevent VAP. Moreover, little is known about what factors influence the use of these strategies (IHI, 2008). Recently, interest has focused on practice care bundles, sets of practices implemented together (Youngquist *et al.*, 2007).

Care bundle is a cohesive set of evidence-based, well-established clinical practices that when implemented together; achieve better patient outcomes than when implemented individually. Each element on its own should have strong scientific support (IHI, 2008).

In adult, the Centers for Disease Control and Prevention (CDC) and American Thoracic Society have published guidelines for the prevention of ventilator associated pneumonia by using adult VAP bundles (CDC, 2004; American Thoracic Society, 2005). Several studies have shown a reduction in VAP after the

guidelines were implemented into a bundle of interventions that were implemented as a single intervention (Kollef, 2004; Resar *et al.*, 2005; Lorente *et al.*, 2007; Omrane *et al.*, 2007; Gastmeier and Geffers, 2007).

VAP bundle is scarce in the pediatric literature. Since, there is evidence that implementing a VAP bundle can result in significant, sustained reductions in VAP rates, hospital length of stay and costs, researchers implemented a modified pediatric VAP bundle, adapted from adult VAP bundle, applicable in Pediatric Intensive Care Unit (PICU).

Therefore, researchers undertook this study in the beginning of March 2011 to decrease the rate of VAP in PICU after initiation of this modified pediatric VAP bundle compared with the VAP rate for the preceding 12 months (2010).

Objective of the study: Adoption and modification of an adult VAP bundle applicable in Pediatric Intensive Care Unit and implementation of this bundle for VAP prevention among ventilated pediatric patients.

MATERIALS AND METHODS

A pre-interventional and post-interventional study was conducted in the Pediatric Intensive Care Unit (PICU) at Makassed General Hospital, Beirut, Lebanon between March 2010 and March 2012.

Design: In this pre-interventional and post-interventional study that included 57 and 50 patients, respectively researchers compared the rates of VAP from March 2010 to March 2011 for a 1 year period before the initiation of the modified pediatric VAP prevention bundle. This rate was compared with the VAP rates after intervention from March 2011 to March 2012 (1 year period).

Intervention: In addition to routine infection control protocols, a modified pediatric VAP bundle, applicable in PICU was adapted from adults for the study. The adult VAP bundle components, adapted from the Institute for Healthcare Improvement (IHI) include the following:

- Hand hygiene
- Close suction system and subglottic suctioning
- Peptic ulcer disease prophylaxis
- Maintain cuff pressures and endotracheal tube maintenance
- Head of bedelevation
- Sedation vacation and readiness to wean assessment
- Deep venous thrombosis prophylaxis (IHI, 2009)

From the earlier adult care bundle, researchers adapted the modified VAP bundle which is composed of the following:

- Hand hygiene and sterile gloves when in contact with secretions and IV intervention
- Close suction system
- Peptic ulcer prophylaxis
- Oro-gastric tube for residual volumes before feeding
- The 15-30° head of bed elevation
- Oral hygiene with antiseptic solution
- Readiness to wean and extubate assessment (Fig. 1)

Inclusion: All pediatric patients, admitted to Pediatric Intensive Care Unit (PICU) between March 2010 and March 2012 and required mechanical ventilation for longer than 48 h were included in the study.

Exclusion: Pediatric patients who were ventilated and had pneumonia upon PICU admission, ventilated ≤48 h, non-invasively ventilated or who died within 48 h of ventilation were excluded from the study.

Measures: Two sets of measures were monitored: process and outcome measures. The process measure reflected the rate of adherence to the ventilator bundle. The outcome measure included the rate of VAP, duration of intubation and the organism responsible for VAP. The definition of VAP was based on the CDC's National Nosocomial Infection Surveillance definitions (CDC, 2005).

Implementation process: Multiple steps were taken to implement the ventilator bundle and include staff education, development of an audit tool, data collection and tracking of the measures. A team approach to drive and maintain the initiative was developed and included the following: infection control professional, critical care nursing, chief residents, chairman of the infection control committee and chairman of pediatric department.

Staff education was accomplished by multiple presentations on VAP, the importance of the VAP bundle and discussion on the VAP elements. After the initial educational session, a working group worked on the development of the VAP bundle checklist. The compliance with the bundle elements was recorded on daily basis using a checklist during rounds (Fig. 1). Feedback was provided by chief residents on compliance with these processes to the PICU team.

Surveillance: Active VAP surveillance continued throughout the study including full blood counts and if indicated, chest X-ray, sputum samples and blood cultures with temperatures ≥38.5°C or <36.0°C. The

Patient's Name: Case number: Date of intubation: Put Yes (Y), No (N) or Not Applicable (NA) for the intervention done				Sticker					
Shift	Day:			Day:			Day:		
Sint	7-3	3-11	11-7	7-3	3-11	11-7	7-3	3-11	11-7
Date of intervention									
Time of intervention									
Hand hygiene before and after intervention, sterile gloves									
Head of bed is elevated 10°-30° (angle indicator), unless contraindicated, reason:									
*Daily assessment of readiness to extubate									
*Patient is on peptic ulcer prophylaxis									
Check orogastric tube for residual volume before each feeding									
Ventilator tubing is free from condensate and water (drain tubes)									
Oral care/assessment (teeth, tongue, hard palate) are performed every 4 h with antiseptic solution									
RN full name									
RN signature									

Fig. 1: Pediatric VAP bundle

bedside nurse was responsible for collecting VAP data over the 12 months period until 24 h post extubation, discharge or death.

VAP definition: VAP was defined as pneumonia occurring >48 h after intubation diagnosed by specific Chest Radiograph (CXR) changes with at least three clinical or laboratory findings. Diagnosis was based on radiological, clinical and laboratory criteria from the CDC's National Nosocomial Infection Surveillance System (CDC, 2005) (Table 1).

Radiological: VAP was suggested by new or progressive pulmonary infiltrates, consolidation or cavitation on at least two serial CXRs with gradual

Table 1: Diagnostic criteria for VAP Radiological+at least three clinical/Laboratory criteria Radiological Clinical/Laboratory New or progressive pulmonary Core temperature ≥38.5°C or <36°C infiltrates, consolidation or (no other recognized cause) Leucopenia or leukocytosis (by age) cavitation on chest radiograph 0 day to 1 week \geq 34×10° L (two or more serial chest X-rays) 1 week to 1 month >19.5 or <5×10 9 L 2-5 years >17.5 or <6×109 L 6-12 years >15.5 or <4.5×10° L 13 to <18 years >11 or <4.5×109 L Significant positive culture from respiratory secretions Relevant culture from alternative site of infection

resolution (rapid resolution suggests non-infective etiology, e.g., pulmonary edema or atelectasis) (CDC, 2005).

^{*}To be checked once daily on day duty

Clinical: Core temperature ≥38.5°C or <36°C hyper/hypothermia was defined as at least two consecutive abnormal readings using standard measurement techniques in a 24 h period not clearly attributable to extra-pulmonary infection, the environment or blood/drug reactions (CDC, 2005).

Laboratory: Leucopenia or leukocytosis was defined by age according to the International Consensus Conference on Pediatric Sepsis statement (Goldstein *et al.*, 2005). Significant culture of respiratory secretions: microbial growth from endotracheal secretions was reported. Sensitivities were performed on any potential respiratory pathogen. Relevant cultures from alternative site of infection: positive blood cultures of likely respiratory tract pathogens, unrelated to another source of infection were considered in the diagnosis of VAP.

RESULTS AND DISCUSSION

A total of 107 pediatric patients were enrolled into the study. The pre-interventional group was 57 patients and the post-interventional group was 50 patients. Baseline demographic information between both groups showed no difference in sex (Table 2). In the pre-interventional group, VAP occurred in 30 patients out of 57, a VAP rate of 52.6 cases per 100 mechanically ventilated patients, compared to 3 out of 50, a VAP rate of 6 cases per 100 mechanically ventilated patients, after implementation of VAP bundle. Thus, there was a statistically significant difference in the rate of VAP between the pre-interventional and post-interventional groups (p<0.0001) (Table 3).

Pediatric patients with VAP had longer duration on ventilation with mean duration of 11.42 ventilator days, compared to 5.18 ventilator days in patients who did not have VAP with statistically significant difference

Table 2: Baseline demographic information of patients with and without VAP

V A A A			
Variables	Before VAP bundle	After VAP bundle	p-value
Number of patients	57	50	-
Gender			
Male	33 (57.9%)	28 (56%)	-
Female	24 (42.1%)	22 (44%)	0.843

Data is presented as mean Standard Deviation (SD) or percentage (%) as appropriate

Table 3: Rates of VAP before and after implementation of pediatric VAP

Dunale			
Variables	Before VAP bundle	After VAP bundle	p-values
Number of patients	57	50	-
VAP	30 (52.6%)	3 (6%)	< 0.0001
No VAP	27 (47.4%)	47 (94%)	< 0.0001

Data is presented as mean (SD)

(p<0.0001) (Table 4). In the pre-interventional group, the Deep Tracheal Aspirates (DTA) cultures of 33 cases of VAP revealed as follows: 12 cases of *Staphylococcus aureus*, 7 cases of *Pseudomonas aeruginosa*, 1 case of *E. coli*, 1 case of *Acinetobacter* sp. and 9 cases with no growth results. In the post-interventional group, the Deep Tracheal Aspirate (DTA) cultures of 3 cases of VAP revealed 2 cases of *Pseudomonas aeruginosa* and 1 case with no growth result (Table 5).

Few data are available on VAP rates in the PICU and reported rates vary for each study, Stover *et al.* (2001) reported an overall rate of 0.9 per 1000 ventilator days in infants (Stover *et al.*, 2001). Cordero *et al.* (2002) found an overall rate of 18.9% among low birth weight infants. The study showed VAP rate of 52% among ventilated pediatric patients before implementation of the modified pediatric VAP bundle.

There was a strong correlation between VAP and duration of ventilator use (Gaynes *et al.*, 1996; Drews *et al.*, 1995). In the study, patients who had VAP had longer stay on mechanical ventilation with a mean of 11.42 ventilator days than those who didn't develop VAP with a mean of 5.18 ventilator days. Other potential risk factors for VAP have been examined in several large studies; the results have differed between study populations (Cook *et al.*, 1998; Elward *et al.*, 2002).

Clinical interventions for monitoring and therapeutic purposes can increase infants' risk of VAP. Placement of the nasogastric tube might enhance nasopharyngeal and gastric colonization with gram-negative bacilli that could be aspirated into the lower airway, initiating VAP (Pingleton et al., 1986) while intravenous catheterization induced colonization as well ลร bloodstream dissemination of organisms (Gaynes et al., 1996; Drews et al., 1995; Stover et al., 2001). Infants who underwent prolonged use of mechanical ventilatory support have potentiated exposure to contaminated respiratory equipment and contact with contaminated or colonized hands of healthcare workers in the PICU (Craven et al., 1990).

 Table 4: Duration of ventilator days between patients with and without VAP

 Variables
 VAP
 Non-VAP
 p-value

 Number of patients
 33.00
 74.00

 Ventilator days
 11.42
 5.18
 <0.0001</td>

 Data is presented as mean (SD)

Table 5: Microorganisms from DTA cultures in patients with VAP

	DTA	Before VAP	After VAP
Organisms	culture	bundle	bundle
No. organism	10 (30.30%)	9 (30.00%)	1 (33.33%)
Staphylococcus aureus	12 (36.36%)	12 (40.00%)	0
Pseudomonas sp.	9 (27.27%)	7 (23.33%)	2 (66.66%)
E. coli sp.	1 (3.03%)	1 (3.33%)	0
Acinetobacter sp.	1 (3.03%)	1 (3.33%)	0

There was a limitation in the sampling procedures used to obtain microbiologic specimens from the small respiratory tract in the study in that invasive techniques to distinguish infection from colonization are not practical or feasible and may be harmful in small infants. They can impair blood gas exchange, delay treatment and lead to sepsis. The role of the Broncho Alveolar Lavage (BAL) in devising a therapeutic strategy superior to one based only on clinical evaluation has not been evaluated in infants (Chastre and Fagon, 2002; Niederman et al., 1994; Sanchez-Nieto et al., 1998). Percutaneous transthoracic aspiration is a definitive diagnostic procedure but is not commonly performed (Dorca et al., 1995). Endotracheal aspirate is the simplest means of obtaining respiratory secretions from infants receiving mechanical ventilation (Papazian et al., 1996).

Gram-negative bacilli comprised nearly the whole isolates from cultures of specimens obtained from endotracheal aspirate and blood. Aerobic gram-negative bacilli are implicated in a wide spectrum of nosocomial infections in the ICU. Their emergence as significant pathogens seems to be related partly to the widespread use of broad-spectrum antibiotics and partly to their ability to develop resistance rapidly to the major groups of antibiotics (Trouillet et al., 1998; Waterer and Wunderink. 2001; Schaberg etal..Coagulase-negative staphylococcus was the gram-positive organism that accounted for the etiology of VAP and was associated with central intravenous catheters (Gaynes et al., 1996; Avila-Figueroa et al., 1998). Multi-resistant strains of Acinetobacter, Klebsiella and Pseudomonas are difficult to treat and are implicated in a wide spectrum of nosocomial infections, predominantly in the ICU (Towner, 1997).

VAP was the most common nosocomial infection contributing to death (Fagon et al., 1996). Mortality depended on duration on ventilator and virulence of pathogen those with longer duration on ventilator were at higher risk. VAP caused by *Pseudomonas aeruginosa* had a higher rate of mortality (Cunha, 2001). Fagon et al. (1996) suggesting that in addition to the severity of underlying medical conditions and nosocomial bacteremia, VAP independently contributes to ICU patient mortality.

Since, some clinical interventions increase the development of VAP, clinical guidelines for the prevention of VAP should be developed (Ibrahim *et al.*, 2001). Pediatricians should understand its epidemiology and participates in control measures by reducing the risk of cross-contamination during mechanical ventilation, preventing colonization and aspiration and caring for enteral tubes and central catheters in sick infants.

In the current study, researchers created a modified VAP bundle applicable to PICU and that resulted in a significant decrease in the VAP rate and maintained such a reduction over 12 months. In Lebanon, no studies were conducted to evaluate the rate of VAP in PICU or to decrease its rate. In this study, researchers observed a high rate of VAP before implementation of VAP bundle reaching 52% of ventilated patients and a significant reduction of VAP rate after implementing VAP bundle down to 6% of ventilated patients. Researchers also observed reduction in the duration of mechanical ventilation that resulted in decrease of hospital length stay in PICU with potential cost avoidance and this inturn improved the outcome and decreased the pediatric morbidity and mortality related to VAP.

CONCLUSION

Researchers adopted a modified pediatric VAP bundle resulting in a marked reduction of the VAP rate. Thus, such measures are effective and require staff training and a multidisciplinary program. A well developed and supported program will enhance the success rate of such interventions, especially if coupled with data feedback.

REFERENCES

- American Thoracic Society, 2005. Guidelines for the management of adults with hospital-acquired, ventilator associated and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med., 171: 388-416.
- Avila-Figueroa, C., D.A. Goldman, D.K. Richardson, J.E. Gray, A.F. Ferrari and J. Freeman, 1998. Intravenous lipid emulsions are the major determinant of coagulase-negative staphylococcal bacteremia in very low birth weight newborns. Pediatric Infect. Dis. J., 17: 10-17.
- CDC, 2004. Guidelines for preventing health-careassociated pneumonia, 2003: Recommendations of CDC and the healthcare infection control practices advisory committee. MMWR Recommendations Rep., 53: 1-36.
- CDC, 2005. Criteria for defining nosocomial pneumonia. NHSN v.1.0, 01-01-05, Centers for Disease Control and Prevention (CDC), Atlanta, GA., USA.
- Chastre, J. and J.Y. Fagon, 2002. Ventilator associated pneumonia. Am. J. Respir Crit. Care Med., 165: 867-903.
- Cook, D.J., S.D. Walter, R.J. Cook, L.E. Griffith and G.H. Guyatt *et al.*, 1998. Incidence of and risk factors for ventilator associated pneumonia in critically ill patients. Ann. Internal Med., 129: 433-440.

- Cordero, L., L.W. Ayers, R.R. Miller, J.H. Seguin and B.D. Coley, 2002. Surveillance of ventilator associated pneumonia in very-low-birth-weight infants. Am. J. Infect. Control, 30: 32-39.
- Craven, D.E., T.W. Barber, K.A. Steger and M.A. Montecalvo, 1990. Nosocomial pneumonia in the 1990s: Update of epidemiology and risk factors. Semin. Respir. Infect., 5: 157-172.
- Cunha, B.A., 2001. Nosocomial pneumonia: Diagnostic and therapeutic considerations. Med. Clin. North Am., 85: 79-114.
- Dorca, J., F. Manresa, L. Esteban, B. Barreiro and E. Prats et al., 1995. Efficacy, safety and therapeutic relevance of transthoracic aspiration with ultrathin needle in nonventilated nosocomial pneumonia. Am. J. Respir. Crit Care Med., 151: 1491-1496.
- Drews, M.B., A.C. Ludwig, J.U. Leititis and F.D. Daschner, 1995. Low birth weight and nosocomial infection of neonates in a neonatal intensive care unit. J. Hosp. Infect., 30: 65-72.
- Elward, A.M., D.K. Warren and V.J. Fraser, 2002. Ventilator associated pneumonia in pediatric intensive care unit patients: Risk factors and outcomes. Pediatrics, 109: 758-764.
- Fagon, J.Y., J. Chastre, A. Vaugnat, J.L. Trouillet, A. Novara and C. Gibert, 1996. Nosocomial pneumonia and mortality among patients in intensive care units. J. Am. Med. Assoc., 275: 866-869.
- Gastmeier, P. and C. Geffers, 2007. Prevention of ventilator associated pneumonia: Analysis of studies published since 2004. J. Hosp. Infect., 67: 1-8.
- Gaynes, R.P., J.R. Edwards, W.R. Jarvis, D.H. Culver, J.S. Tolson and W.J. Martone, 1996. Nosocomial infections among neonates in high-risk nurseries in the United States. Pediatrics, 98: 357-361.
- Goldstein, B., B. Giroir and A. Randolph, 2005. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatric Crit. Care Med., 6: 2-8.
- Grohskopf, L.A., R.L. Sinkowitz-Cochran, D.O. Garrett, A.H. Sohn and G.L. Levine *et al.*, 2002. A national point-prevalence survey of pediatric intensive care unit-acquired infections in the United States. J. Pediatrics, 140: 432-438.
- IHI, 2008. Getting started kit: Prevent ventilator associated pneumonia. How-to guide. Institute for Healthcare Improvement (IHI), Cambridge, MA., USA.
- IHI, 2009. Implement the IHI ventilator bundle. Institute for Healthcare Improvement (IHI), Cambridge, MA., USA.

- Ibrahim, E.H., S. Ward, G. Sherman, R. Schaiff, V.J. Fraser and M.H. Kollef, 2001. Experience with a clinical guideline for the treatment of ventilator associated pneumonia. Crit. Care Med., 29: 1109-1115.
- Kollef, M.H., 2004. Prevention of hospital-associated pneumonia and ventilator associated pneumonia. Crit. Care Med., 32: 1396-1405.
- Lorente, L., S. Blot and J. Rello, 2007. Evidence on measures for the prevention of ventilator associated pneumonia. Eur. Respir. J., 30: 1193-1207.
- Niederman, M.S., A. Torres and W. Summer, 1994. Invasive diagnostic testing is not needed routinely to manage suspected ventilator associated pneumonia. Am. J. Respir. Crit. Care Med., 150: 565-569.
- Omrane, R., J. Eid, M.M. Perreault, H. Yazbeck, D. Berbiche, A. Gursahaney and Y. Moride, 2007. Impact of a protocol for prevention of ventilator associated pneumonia. Ann. Pharmacother., 41: 1390-1396.
- Papazian, L., F. Bregenon, X. Thirion, R. Gregoire and P. Saux et al., 1996. Effect of ventilator associated pneumonia on mortality and morbidity. Am. J. Respir. Crit. Care Med., 154: 91-97.
- Payne, N.R., J.H. Carpenter, G.J. Badger, J.D. Horbar and J. Rogowski, 2004. Marginal increase in cost and excess length of stay associated with nosocomial bloodstream infections in surviving very low birth weight infants. Pediatrics, 114: 3488-3455.
- Petdachai, W., 2004. Ventilator associated pneumonia in a newborn intensive care unit. Southeast Asian J. Trop. Med. Public Health, 35: 724-729.
- Pingleton, S.K., D.R. Hinthorn and C. Liu, 1986. Enteral nutrition in patients receiving mechanical ventilation: Multiple sources of tracheal colonization include the stomach. Am. J. Med., 80: 827-832.
- Resar, R., P. Pronovost, C. Haraden, T. Simmonds, T. Rainey and T. Nolan, 2005. Using a bundle approach to Improve ventilator care processes and reduce ventilator associated pneumonia. Joint Commission J. Qual. Patient Saf., 31: 243-248.
- Sanchez-Nieto, J.M., A. Torres, F. Garcia-Cordoba, M. El-Ebiary and A. Carrillo et al., 1998. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator associated pneumonia: A pilot study. Am. J. Respir. Crit. Care Med., 157: 371-376.
- Schaberg, D.R., D.H. Culver and R.P. Gaynes, 1991. Major trends in the microbial etiology of nosocomial infection. Ann. J. Med., 91: 72S-75S.

- Stoll, B.J., N.I. Hansen, I. Adams-Chapman, A.A. Fanaroff and S.R. Hintz et al., 2004. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. J. Am. Med. Assoc., 292: 2357-2365.
- Stover, B.H., S.T. Shulman, D.F. Bratcher, M.T. Brady, G.L. Levine and W.R. Jarvis, 2001. Nosocomial infection rates in US children's hospitals' neonatal and pediatric intensive care units. Am. J. Infect. Control, 29: 152-157.
- Towner, K.J., 1997. Clinical importance and antibiotic resistance of *Acinetobacter* spp.: Proceedings of a symposium held on 4-5 November 1996 at Eilat, Israel. J. Med. Microbiol., 46: 721-746.
- Trouillet, J.L., J. Chastre, A. Vuagnat, M.L. Joly-Guillou, D. Combaux, M.C. Dombret and C. Gibert, 1998. Ventilator associated pneumonia caused by potentially drug-resistant bacteria. Am. J. Respir. Crit. Care Med., 157: 531-539.

- Van der Zwet, W.C., A.M. Kaiser, R.M. Van Elburg, J. Berkhof, W.P.F. Fetter, G.A. Parlevliet and C.M.J.E. Vandenbroucke-Grauls, 2005. Nosocomial infections in a Dutch neonatal intensive care unit: Surveillance study with definitions for infection specifically adapted for neonates. J. Hosp. Infect., 61: 300-311.
- Vincent, J.L., D. Bihari, P.M. Suter, H.A. Bruining and J. White *et al.*, 1995. The prevalence of nosocomial infection in intensive care units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) study.. J. Am. Med. Assoc., 274: 639-644.
- Waterer, G.W. and R.G. Wunderink, 2001. Increasing threat of gram-negative bacteria. Crit. Care Med., 29: N75-N81.
- Youngquist, P., M. Carroll, M. Farber, D. Macy, P. Madrid, J. Ronning and A. Susag, 2007. Implementing a ventilator bundle in a community hospital. Joint Commission J. Qual. Patient Saf., 33: 219-225.